Journal of Immunology Research
Volume 2019 (2019), Article ID 2546161, 25 pages
https://doi.org/10.1155/2019/2546161

Review Article

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Fan Bai, Gang Gang Li, Qingmin Liu, Xinwu Niu, Ruilian Li, and Huiqun Ma

The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Correspondence should be addressed to Huiqun Ma; mahuiqun@mail.xjtu.edu.cn

Received 26 October 2018; Revised 10 January 2019; Accepted 14 February 2019; Published 10 September 2019

Academic Editor: Jacek Tabarkiewicz

Copyright © 2019 Fan Bai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Background. The role of interleukin-12 (IL-12), interleukin-23 (IL-23), and interleukin-17 (IL-17) has been recognized in psoriasis pathogenesis, and new drugs targeting this axis have already been developed which may provide a new therapeutic approach for patients with moderate to severe psoriasis. Objective. To compare the direct and indirect evidences of the efficacy and safety of brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab in the short-term treatment of moderate to severe plaque psoriasis using network meta-analysis (NMA). Methods. A comprehensive literature search was performed in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for the available relevant studies. NMA was conducted by Stata 15.0 software using relative risks (RR) with 95% confidence interval to assess the clinical effectiveness and safety. Ranked the efficacy and safety for each drug accordance with the surface under the cumulative ranking curve (SUCRA). Results. This meta-analysis included 28 studies. All the interventions performed better than placebo in short-term achievement. Based on the result of SUCRA, ixekizumab 80 mg every 2 weeks ranked the highest in short-term achievement of PASI 75 (SUCRA = 93.0%). Brodalumab 210 mg ranked the highest in short-term achievement of PASI 100 (SUCRA = 85.0%). Secukinumab 300 mg ranked the highest in short-term achievement of sPGA 0/1 or IGA 0/1 or PGA 0/1 (SUCRA = 98.1%). In terms of having a risk of adverse events, the rates were higher in brodalumab, secukinumab, ixekizumab, and ustekinumab 45 mg compared with placebo. Ixekizumab 80 mg every 4 weeks ranked the highest in the risk of adverse events during short-term treatment (SUCRA = 4.5%). Guselkumab 50 mg ranked the highest in the risk of serious adverse events during short-term treatment (SUCRA = 25.9%). Ixekizumab 80 mg every 4 weeks ranked the highest in the risk of discontinuations due to adverse events during short-ter treatment (SUCRA = 10.7%). Conclusions. IL-17, IL-12/23, and IL-23 inhibitors had high efficacy in the achievement of PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 in moderate to severe plaque psoriasis after 12 or 16 weeks of treatment. IL-17 inhibitors showed superior efficacy. However, its clinical safety was poor. Risankizumab appeared to have relatively high efficacy and low risk. The clinical tolerance of other biological agents needs to be further observed.

1. Introduction

Psoriasis is a common chronic inflammatory skin disease whose main pathological manifestations were inflammation, hyperproliferation of the epidermis, altered maturation of the epidermis, and vascular alterations [1]. The prevalence of this disease ranges from 0.51% to 11.43% in different countries [2]. Itching is the main symptom in different degrees; it has a great influence on the quality of life of patients and easily leads to social and psychological disorder such as inferiority, depression, and anxiety [3]. The pathogenesis of psoriasis is always believed to be a combination of immunologic disarrangement, psoriasis-associated susceptibility loci, psoriasis autoantigens, and multiple environmental factors; however, current research shows that psoriasis is a T-cell mediated disease primarily driven by pathogenic T-cells [4]. In an animal experiment, it is observed in the imiquimod-induced psoriasis-like mice that the epidermal expression of IL-23, IL-17A, and IL-17F is increased, whereas disease development was almost completely blocked in mice deficient for IL-23 or the IL-17 receptor [5]. Moreover, some of these studies did explore that IL-23 which is secreted by dermal dendritic cells (DDC) can induce the activation of Th17 lymphocytes and lead to the release of proinflammatory cytokines such as IL-17A, IL-17F, IL-22, IL-26, TNF-α, and IFN-γ. The complex interactions of these cytokines ultimately lead to epidermal hyperplasia, recruitment of neutrophils, and angiogenesis [6]. Recently, several studies have investigated that IL-12 and IL-23 share a common subunit (p40). Transgenic mice that overexpress IL-12 p40 develop inflammatory skin lesions [7]. Therefore, based on the theory of IL-12 and IL-23/IL-17 signal transduction pathway, blocking the important loci of signal axis has become a potential therapy to destroy the inflammatory cycle of psoriasis.

Fortunately, IL12/23, IL-17, and newer IL-23p19 antagonists have been produced and applied in clinics which shows a translational revolution in the treatment and management of psoriasis. Several studies have summarized the efficacy and safety data of IL-17 and IL-23 agents, but the results are inadequate [8, 9]. In addition, other NMA were made at the class level of medications, but not at the dosage level [10]. Therefore, we perform a systematic review with the NMA of all randomized trials to compare short-term treatment efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab at the dosage level for moderate to severe plaque psoriasis.

2. Materials and Methods

2.1. Study Identification

Our NMA was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [11].

A computer-based literature search was performed to identify the available relevant studies published before August 1, 2018, in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trials registered at ClinicalTrials.gov were searched for details of any relevant clinical trials in progress. We used the terms “ustekinumab or stelara or CNTO 1275 or guselkumab or tildrakizumab or SCH 900222 or MK-3222 or risankizumab or BI 655066 or secukinumab or cosentyx or AIN 457 or brodalumab or siliq or AMG-827 or lumicef or ixekizumab or taltz or LY2439821” and “psoriasis.” Vocabulary and syntax were adapted to be appropriate for each database. Standardized filters were applied for study designs, including the Cochrane highly sensitive search strategy for randomized controlled trials. Language was restricted to English. Comments, editorials, and letters were removed. The search strategy was shown in Supplementary Table 1.

2.2. Study Selection

We determined the inclusion and exclusion criteria before the search. The included studies should fulfill the following criteria: study design was limited to randomized, double-blind, placebo-controlled trials; adult patients ( years) are of either sex with a diagnosis of moderate to severe plaque psoriasis; the study should provide at least one efficacy outcome for short-term treatment: (1) 75% or greater reduction from baseline in the psoriasis area and severity index (PASI 75), (2) 100% reduction from baseline in the psoriasis area and severity index (PASI 100), (3) static physician’s global assessment score of 0 or 1 (sPGA 0/1), (4) modified investigator’s global assessment score of 0 or 1 (IGA 0/1), and (5) physician’s global assessment score of 0 or 1 (PGA 0/1); the study should provide at least one safety outcome for short-term treatment: (1) one or more adverse events (AEs), (2) one or more serious adverse events (sAEs), and (3) discontinuations due to AEs. The exclusion criteria were as follows: the patients with psoriasis were under 18 years of age.

2.3. Data Abstraction and Quality Assessment

Two independent investigators abstracted the data using a standard data extraction form, and any disagreement will be resolved by a third author. The following information will be extracted from each included article: author, year of publication, journal, drug, time to evaluate, primary endpoint, details of the interventions, sample size, male proportion, age, duration of psoriasis, involved body surface area (%), and baseline psoriasis area and severity index (PASI) score.

Two authors independently assessed the quality of each included study in accordance with the Cochrane handbook of systematic reviews of interventions 5.1.0 (updated March 2011), which covers the following: (1) random sequence generation (selection bias), (2) allocation concealment (selection bias), (3) blinding of participants and treatment providers (performance bias), (4) blinding of outcome assessors (detection bias), (5) incomplete outcome data (attrition bias), (6) selective reporting (reporting bias), and (7) other biases. Disagreements between the review authors over the risk of bias in particular studies were resolved by a third review author.

2.4. Statistical Analysis

Clinical data were synthesized through narrative review with tabulation of the results of the included studies. Where sufficient clinically and statistically homogenous data were available, data were pooled using appropriate meta-analytic techniques.

Stata V.15.0 (StataCorp, College Station, TX, USA) [12] in a frequentist framework was used to perform network meta-analysis (NMA) which can make direct and indirect evidences comparable. No matter what interventions the subjects actually received, they were grouped according to the initial random statistics. If only percentages were reported, the results were estimated according to the nearest total number of events. When there was a missing value, we contacted the authors to provide the missing outcome data. Otherwise, the treatment was assumed to fail. We used the netleague command to report the RRs with corresponding 95% confidence intervals (CIs) between two comparisons, and the results were presented in a tabular form. We also ranked the efficacy and safety for each drug. The surface under the cumulative ranking curve (SUCRA) ranges from 0% to 100% were determined as an estimation of the ranking probability for each medication. For efficacy indicators, the larger the area under the curve, the better the effect. For safety indicators, the larger the area under the curve, the better the tolerance. The inconsistency and statistical disagreement between direct and indirect evidences were performed by the loop-specific method in each loop locally. And the relative odds ratio (ROR) with 95% CIs could be used to calculate clinical authenticity of NMA. If the ROR is close to 1 or the 95% CIs include 0, the similar effect estimations for direct evidence and indirect evidence are consistent [13]. Additional sensitivity analyses were performed by excluding the trials at the high risk of bias to evaluate the robustness of our findings. Publication bias was estimated by comparison-adjusted funnel plots.

3. Results

3.1. Search Strategy

In total, 6801 publications matching the search criteria were identified. After removing the duplicate publications, titles and abstracts of the remaining 4945 publications were screened. 4899 publications were irrelevant records, and 46 publications were ultimately determined with eligibility. Based on the inclusion and exclusion criteria, 23 articles including 28 randomized, double-blind, placebo-controlled clinical trials were assessed in this meta-analysis [14–36]: 5 trials of brodalumab, 5 trials of secukinumab, 3 trials of ixekizumab, 6 trials of ustekinumab, 4 trials of guselkumab, 3 trials of tildrakizumab, and 2 trials of risankizumab. The flowchart for the selection of eligible studies is shown in Figure 1.

Figure 1: Flowchart for the selection of eligible studies.

The characteristics of the included studies are shown in Table 1. 19840 patients with psoriasis in 28 trials were included in this meta-analysis. Except 7 phase II trials, the rest were all phase III trials. 21 trials evaluated the short-term outcomes at weeks 12 and 7 trials at weeks 16. We collected the major clinical responses and safety indicators such as PASI 75, PASI 100, sPGA 0/1, IGA 0/1, PGA 0/1, AEs, SAEs, and discontinuations due to AEs in Table 2.

Table 1: Characteristics of the included studies.

Author
Year
Journal
Drug
Time to evaluate
Primary endpoint
Group
Total
Male, (%)
Age (mean age)
Duration of psoriasis (years)
Involved body surface area (%)
Baseline PASI score

Papp (AMAGINE-1)
2016
BJD
Brodalumab
12
PASI 75
210 mg
222
161 (73)

sPGA 0/1
140 mg
219
162 (74)

Placebo
220
161 (73)

Lebwohl (AMAGINE-2)
2015
NEJM
Brodalumab
12
PASI 75
210 mg
612
421 (69)

sPGA 0/1
140 mg
610
413 (68)

PASI 100
Ustekinumab
300
205 (68)

Placebo
309
219 (71)

Lebwohl (AMAGINE-3)
2015
NEJM
Brodalumab
12
PASI 75
210 mg
624
431 (69)

sPGA 0/1
140 mg
629
437 (70)

PASI 100
Ustekinumab
313
212 (68)

Placebo
315
208 (66)

Papp
2012
NEJM
Brodalumab
12
PASI 75
210 mg
39
28 (72)

PASI 100
140 mg
39
22 (56)

Placebo
42
30 (71)

Nakagawa
2015
JDS
Brodalumab
12
PASI 75
210 mg
37
29 (78.4)

PASI 100
140 mg
37
30 (81.1)

sPGA 0/1
Placebo
38
27 (71.1)

Rich
2012
BJD
Secukinumab
12
PASI 75
150 mg
133
105 (78.9)

Placebo
67
44 (65.7)

Paul (JUNCTURE)
2015
JEADV
Secukinumab
12
PASI 75
300 mg
60
46 (76.7)

IGA 0/1
150 mg
61
41 (67.2)

Placebo
61
38 (62.3)

Langley (ERASURE)
2014
NEJM
Secukinumab
12
PASI 75
300 mg
245
169 (69.0)

IGA 0/1
150 mg
245
168 (68.6)

Placebo
248
172 (69.4)

Langley (FIXTURE)
2014
NEJM
Secukinumab
12
PASI 75
300 mg
327
224 (68.5)

IGA 0/1
150 mg
327
236 (72.2)

Placebo
326
237 (72.7)

Blauvelt (FEATURE)
2015
BJD
Secukinumab
12
PASI 75
300 mg
59
38 (64.4)

IGA 0/1
150 mg
59
40 (67.8)

Placebo
59
39 (66.1)

Gordon (UNCOVER-1)
2016
NEJM
Ixekizumab
12
PASI 75
80 mg Q4W
432
289 (66.9)

sPGA 0/1
80 mg Q2W
433
291 (67.2)

Placebo
431
303 (70.3)

Griffiths (UNCOVER-2)
2015
Lancet
Ixekizumab
12
PASI 75
80 mg Q4W
347
244 (70.3)

sPGA 0/1
80 mg Q2W
351
221 (63.0)

Placebo
168
120 (71.4)

Griffiths (UNCOVER-3)
2015
Lancet
Ixekizumab
12
PASI 75
80 mg Q4W
386
258 (66.8)

sPGA 0/1
80 mg Q2W
385
254 (66.0)

Placebo
193
137 (71.0)

IGARASHI
2012
JD
Ustekinumab
12
PASI 75
45 mg
64
53 (82.8)
45

90 mg
62
47 (75.8)
44

Placebo
32
26 (83.9)
49

Leonardi (PHOENIX 1)
2008
Lancet
Ustekinumab
12
PASI 75
45 mg
255
175 (68·6)
44.8
19.7
27.2
20.5

90 mg
256
173 (67·6)
46.2
19.6
25.2
19.7

Placebo
255
183 (71·8)
44.8
20.4
27.7
20.4

Papp (PHOENIX 2)
2008
Lancet
Ustekinumab
12
PASI 75
45 mg
409
283 (69·2)
45.1
19.3
25.9
19.4

90 mg
411
274 (66·7)
46.6
20.3
27.1
20.1

Placebo
410
283 (69·0)
47.0
20.8
26.1
19.4

Tsai (PEARL)
2011
JDS
Ustekinumab
12
PASI 75
45 mg
61
50 (82.0)

Placebo
60
53 (88.3)

Zhu (LOTUS)
2013
JDD
Ustekinumab
12
PASI 75
45 mg
160
125 (78.1)

Placebo
162
123 (75.9)

Krueger
2007
NEJM
Ustekinumab
12
PASI 75
45 mg
64
39 (61)

90 mg
64
52 (81)

Placebo
64
46 (72)

Blauvelt (VOYAGE 1)
2017
JAAD
Guselkumab
16
IGA 0/1
100 mg
329
240 (72.9)

PASI 90
Placebo
174
119 (68.4)

Reich (VOYAGE 2)
2017
JAAD
Guselkumab
16
IGA 0/1
100 mg
496
349 (70.4)

PASI 90
Placebo
248
173 (69.8)

Gordon
2015
NEJM
Guselkumab
16
PGA 0/1
50 mg
42
28 (67)
43
19
25
19

100 mg
42
31 (74)
42
18
24
21

Placebo
42
28 (67)
46.5
18
28
22

OHTSUKI
2017
JD
Guselkumab
16
IGA 0/1
50 mg
65
44 (67.7)
50.1
15.25
38.0
25.60

PASI 90
100 mg
63
47 (74.6)
47.8
14.39
37.9
26.73

Placebo
64
54 (84.4)
48.3
13.66
33.6
25.92

Papp
2015
BJD
Tildrakizumab
16
PASI 75
100 mg
89
76 (85)

NR
NR
NR

200 mg
86
65 (76)

NR
NR
NR

Placebo
46
38 (83)

NR
NR
NR

Reich (reSURFACE 1)
2017
Lancet
Tildrakizumab
12
PASI 75
100 mg
309
207 (67)
46.4
NR
29.7
20.0

PGA 0/1
200 mg
308
226 (73)
46.9
NR
30.9
20.7

Placebo
155
100 (65)
47.9
NR
29.6
19.3

Reich (reSURFACE 2)
2017
Lancet
Tildrakizumab
12
PASI 75
100 mg
307
220 (72)
44.6
NR
34.2
20.5

PGA 0/1
200 mg
314
225 (72)
44.6
NR
31.8
19.8

Placebo
313
222 (71)
45.8
NR
31.6
20.2

Gordon (UltIMMa-1)
2018
Lancet
Risankizumab
16
PASI 90
150 mg
304
212 (70)
48.3
NR
26.2
20.6

sPGA 0/1
Ustekinumab
100
70 (70)
46.5
NR
25.2
20.1

Placebo
102
79 (77)
49.3
NR
27.9
20.5

Gordon (UltIMMa-1)
2018
Lancet
Risankizumab
16
PASI 90
150 mg
294
203 (69)
46.2
NR
26.2
20.5

sPGA 0/1
Ustekinumab
99
66 (67)
48.6
NR
20.9
18.2

Placebo
98
67 (68)
46.3
NR
23.9
18.9

Data are presented as the numbers (%) or the . PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 90: the percentages of patients with a 90% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; Q2W: every 2 weeks; Q4W: every 4 weeks; NR: not reported.

Table 2: Summary of pooled major clinical responses and adverse events during short-time treatment.

Author
Drug
Time to evaluate
Group
Total
PASI 75
PASI 100
sPGA 0/1
IGA 0/1
PGA 0/1
AEs
sAEs
Discontinuations due to AEs

Papp (AMAGINE-1)
Brodalumab
12
210 mg
222
185
93
168
NR
NR
131
4
2

140 mg
219
132
51
118
NR
NR
126
6
3

Placebo
220
6
1
3
NR
NR
112
3
3

Lebwohl (AMAGINE-2)
Brodalumab
12
210 mg
612
528
272
481
NR
NR
354
6
3

140 mg
610
406
157
354
NR
NR
365
13
4

Ustekinumab
300
210
65
183
NR
NR
177
4
2

Placebo
309
25
2
12
NR
NR
165
8
0

Lebwohl (AMAGINE-3)
Brodalumab
12
210 mg
624
531
229
497
NR
NR
353
9
4

140 mg
629
435
170
377
NR
NR
329
10
4

Ustekinumab
313
217
19
179
NR
NR
168
2
1

Placebo
315
19
1
13
NR
NR
152
3
0

Papp
Brodalumab
12
210 mg
40
33
25
32
NR
NR
33
1
0

140 mg
39
30
15
33
NR
NR
27
0
0

Placebo
38
0
0
1
NR
NR
23
1
0

Nakagawa
Brodalumab
12
210 mg
37
35
22
35
NR
NR
27
1
0

140 mg
37
29
13
29
NR
NR
21
0
0

Placebo
38
3
0
2
NR
NR
17
1
1

Rich
Secukinumab
12
150 mg
133
72
NR
NR
49
NR
89
6
3

Placebo
67
1
NR
NR
1
NR
47
1
1

Paul (JUNCTURE)
Secukinumab
12
300 mg
60
52
16
NR
44
NR
42
1
0

150 mg
61
44
10
NR
33
NR
39
3
0

Placebo
61
2
0
NR
0
NR
33
1
1

Langley (ERASURE)
Secukinumab
12
300 mg
245
200
70
NR
160
NR
135
4
5

150 mg
245
174
31
NR
125
NR
148
4
4

Placebo
248
11
2
NR
6
NR
116
4
4

Langley (FIXTURE)
Secukinumab
12
300 mg
327
249
78
NR
202
NR
181
4
4

150 mg
327
219
47
NR
167
NR
191
7
2

Placebo
326
16
0
NR
9
NR
163
6
3

Blauvelt (FEATURE)
Secukinumab
12
300 mg
59
46
25
NR
41
NR
30
3
1

150 mg
59
41
5
NR
31
NR
34
0
0

Placebo
59
0
0
NR
0
NR
28
1
1

Gordon (UNCOVER-1)
Ixekizumab
12
80 mg Q4W
432
357
145
330
NR
NR
264
12
10

80 mg Q2W
433
386
153
354
NR
NR
257
6
10

Placebo
431
17
2
14
NR
NR
210
5
6

Griffiths (UNCOVER-2)
Ixekizumab
12
80 mg Q4W
347
269
107
253
NR
NR
204
8
5

80 mg Q2W
351
315
142
292
NR
NR
216
5
4

Placebo
168
4
1
4
NR
NR
89
2
1

Griffiths (UNCOVER-3)
Ixekizumab
12
80 mg Q4W
386
325
135
291
NR
NR
215
6
9

80 mg Q2W
385
336
145
310
NR
NR
205
9
8

Placebo
193
14
0
13
NR
NR
70
5
2

IGARASHI
Ustekinumab
12
45 mg
64
38
NR
NR
NR
37
42
0
0

90 mg
62
42
NR
NR
NR
43
37
3
4

Placebo
32
2
NR
NR
NR
3
21
2
2

Leonardi (PHOENIX 1)
Ustekinumab
12
45 mg
255
171
32
NR
NR
154
147
2
1

90 mg
256
170
28
NR
NR
158
131
4
4

Placebo
255
8
0
NR
NR
10
123
2
6

Papp (PHOENIX 2)
Ustekinumab
12
45 mg
409
273
74
NR
NR
278
217
8
1

90 mg
411
311
75
NR
NR
302
197
5
6

Placebo
410
15
0
NR
NR
20
204
8
8

Tsai (PEARL)
Ustekinumab
12
45 mg
61
41
5
NR
NR
43
40
0
0

Placebo
60
3
0
NR
NR
5
42
2
3

Zhu(LOTUS)
Ustekinumab
12
45 mg
160
132
38
NR
NR
126
68
1
3

Placebo
162
18
1
NR
NR
24
62
1
2

Krueger
Ustekinumab
12
45 mg
64
43
10
NR
NR
46
49
2
1

90 mg
64
52
13
NR
NR
53
42
3
1

Placebo
64
1
0
NR
NR
0
48
1
2

Blauvelt (VOYAGE 1)
Guselkumab
16
100 mg
329
300
123
NR
280
NR
170
8
4

Placebo
174
10
1
NR
12
NR
86
3
2

Reich (VOYAGE 2)
Guselkumab
16
100 mg
496
328
169
NR
417
NR
235
8
7

Placebo
248
20
2
NR
21
NR
111
3
2

Gordon
Guselkumab
16
50 mg
42
34
8
NR
NR
33
21
3
NA

100 mg
42
33
14
NR
NR
36
19
0
5

Placebo
42
2
0
NR
NR
3
22
1
3

OHTSUKI
Guselkumab
16
50 mg
65
58
21
NR
60
NR
30
1
1

100 mg
63
53
17
NR
56
NR
29
1
0

Placebo
64
4
0
NR
5
NR
36
2
6

Papp
Tildrakizumab
12
100 mg
89
54
NA
NR
NR
55
58
1
1

200 mg
86
62
NA
NR
NR
64
54
2
1

Placebo
46
2
NA
NR
NR
1
31
0
1

Reich (reSURFACE 1)
Tildrakizumab
12
100 mg
309
197
43
NR
NR
179
146
5
0

200 mg
308
192
43
NR
NR
182
130
8
5

Placebo
155
9
2
NR
NR
11
74
1
1

Reich (reSURFACE 2)
Tildrakizumab
12
100 mg
307
188
38
NR
NR
168
136
4
3

200 mg
314
206
37
NR
NR
186
155
6
3

Placebo
156
9
0
NR
NR
7
86
4
2

Gordon (UltIMMa-1)
Risankizumab
16
150 mg
304
264
109
267
NR
NR
151
7
2

Ustekinumab
100
70
12
63
NR
NR
50
8
2

Placebo
102
10
0
8
NR
NR
52
3
4

Gordon (UltIMMa-2)
Risankizumab
16
150 mg
294
261
149
246
NR
NR
134
6
1

Ustekinumab
99
69
24
62
NR
NR
53
3
0

Placebo
98
8
2
5
NR
NR
45
1
1

PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events; Q2W: every 2 weeks; Q4W: every 4 weeks; NR: not reported; NA: not available.

3.2. Risk of Bias

We summarized the risk of bias in Figure 2.

Figure 2: Risk of bias summary.

3.2.1. Random Sequence Generation

Among the 28 studies, the patients in 22 studies [14–17, 19, 21–23, 25–27, 31–36] were randomized via computer-programmed random sequence or random number generator and were thus evaluated having the low risk of bias. Five studies [18, 20, 28–30] did not mention the method or detail of random sequence generation and were evaluated having an unclear risk of bias. The patients in 1 study [24] were not administered in a blinded, placebo-controlled manner evaluated as the high risk of bias.

3.2.2. Allocation Concealment

11 studies [14, 16, 17, 33–36] used a validated system that automated the random assignment of medication numbers or sequentially numbered containers and were given a low risk of bias; 16 studies [18–32] did not describe any method to blind the random sequence and were evaluated having an unclear risk of bias. One study [15] divided the patients in turns and was regarded having a high risk of bias.

3.2.3. Blinding of Participants and Treatment Providers

One study [29] did not specify how to perform blinding and was regarded having an unclear risk of bias; the rest of the studies were all double or triple blinded with a low risk of bias.

3.2.4. Blinding of Outcome Assessors

21 studies [14–17, 23, 24, 29–36] specified that the evaluators are blinded and were given a low risk of bias. Seven studies [18–22, 25, 28] only blinded the participants and personnel and were given a high risk of bias.

3.2.5. Incomplete Outcome Data

Four studies [15, 16, 23] did not report the reasons for missing data and were given a high risk of bias. The rest of the studies which performed the statistical analysis of data based on intention to treat were regarded having a low risk of bias.

3.2.6. Selective Reporting

One study [23] did not preset the major outcome indicators, so we considered the quality of this study as a high risk of bias; the rest of the studies registered the protocol and reported the main outcomes and were evaluated having a low risk of bias.

3.2.7. Other Biases

The evidence to judge the other biases was not enough, so we regarded the other biases of all the studies as an unclear risk of bias.

3.3. Network Meta-Analysis

3.3.1. Network Plot

We built 6 networks involving 6 major outcomes. And each network plot involved 13 different dosages of 7 different biologics. The summarized network plots of the comparisons are provided in Figure 3. The number of both studies and subjects on ustekinumab 45 mg was the most frequent among all the interventions.

(a) PASI 75

(b) PASI 100

(c) sPGA 0/1 or IGA 0/1 or PGA 0/1

(d) AEs

(e) sAEs

(f) Discontinuations due to AEs

Figure 3: Network plots for all the evaluated outcomes at 12 or 16 weeks. The sizes of the nodes are weighted by the sample of interventions, and the widths of lines are weighed by the number of the studies involved. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events. Alphabetic reference: A, brodalumab 140 mg; B, brodalumab 210 mg; C, guselkumab 100 mg; D, guselkumab 50 mg; E, ixekizumab 80 mg Q2W; F, ixekizumab 80 mg Q4W; G, placebo; H, risankizumab 150 mg; I, secukinumab 150 mg; J, secukinumab 300 mg; K, tildrakizumab 100 mg; L, tildrakizumab 200 mg; M, ustekinumab 45 mg; and N, ustekinumab 90 mg.

(1) PASI 75. With regard to PASI 75, all the interventions performed better than placebo, and the effect size was the strongest for ixekizumab 80 mg every 2 weeks (, 95% CI 13.46, 25.80) and secukinumab 300 mg (, 95% CI 12.79, 25.81). In the mixed comparisons, ixekizumab 80 mg every 2 weeks was superior compared with ixekizumab 80 mg every 4 weeks (, 95% CI 1.04, 1.14), ustekinumab 90 mg (, 95% CI 1.05, 2.22), ustekinumab 45 mg (, 95% CI 1.17, 2.45), guselkumab 100 mg (, 95% CI 1.09, 2.72), guselkumab 50 mg (, 95% CI 1.02, 2.61), and brodalumab 140 mg (, 95% CI 1.20, 2.53). Secukinumab 300 mg was more effective than secukinumab 150 mg (, 95% CI 1.07, 1.23), ustekinumab 45 mg (, 95% CI 1.11, 2.45), guselkumab 100 mg (, 95% CI 1.04, 2.70), and brodalumab 140 mg (, 95% CI 1.14, 2.52). Risankizumab 150 mg performed better than ustekinumab 45 mg (, 95% CI 1.12, 1.37) and brodalumab 140 mg (, 95% CI 1.12, 1.44). There was no significant difference in the efficacy of ixekizumab 80 mg every 2 weeks and secukinumab 300 mg (, 95% CI 0.60, 1.57). Network meta-analysis results for PASI 75 are presented in Figure 4. The corresponding forest plot is detailed in Supplementary Figure 1.

Figure 4: Relative risk with 95% CIs of all interventions from network meta-analysis for PASI 75. Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if , it favors the column defining treatment. In contrast, if , it favors the row defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.

(2) PASI 100. With regard to PASI 100, all the interventions were significantly superior than placebo. The effect size was the strongest for ixekizumab 80 mg every 2 weeks (, 95% CI 27.65, 241.26) and brodalumab 210 mg (, 95% CI 38.76, 147.04). In the mixed comparisons, brodalumab 210 mg was more effective than brodalumab 140 mg (, 95% CI 1.27, 2.04), ustekinumab 90 mg (, 95% CI 1.78, 4.98), ustekinumab 45 mg (, 95% CI 2.10, 4.46), tildrakizumab 200 mg (, 95% CI 1.26, 23.31), and tildrakizumab 100 mg (, 95% CI 1.23, 22.80). Brodalumab 140 mg performed better than ustekinumab 90 mg (, 95% CI 1.11, 3.10) and ustekinumab 45 mg (, 95% CI 1.31, 2.78). Ixekizumab 80 mg every 2 weeks was found to be more efficacious than tildrakizumab 200 mg (, 95% CI 1.08, 31.81) and tildrakizumab 100 mg (, 95% CI 1.06, 31.11). Network meta-analysis results for PASI 100 are presented in Figure 5. The corresponding forest plot is detailed in Supplementary Figure 2.

Figure 5: Relative risk with 95% CIs of all interventions from network meta-analysis for PASI 100. Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if , it favors the column defining treatment. In contrast, if , it favors the row defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.

(3) sPGA 0/1 or IGA 0/1 or PGA 0/1. With regard to sPGA 0/1 or IGA 0/1 or PGA 0/1, the biologics involved were statistically significantly superior to placebo. The effect size was the strongest for secukinumab 300 mg (, 95% CI 16.51, 42.54) and secukinumab 150 mg (, 95% CI 13.10, 33.85). In the mixed comparisons, secukinumab 300 mg was more effective than secukinumab 150 mg (, 95% CI 1.15, 1.38), ustekinumab 90 mg (, 95% CI 1.36, 3.79), tildrakizumab 200 mg (, 95% CI 1.30, 4.72), risankizumab 150 mg (, 95% CI 1.09, 3.06), guselkumab 100 mg (, 95% CI 1.39, 4.25), and brodalumab 210 mg (, 95% CI 1.10, 3.05). Brodalumab 210 mg performed better than ustekinumab 90 mg (, 95% CI 1.13, 1.37) and ustekinumab 45 mg (, 95% CI 1.26, 1.45). Network meta-analysis results for sPGA 0/1 or IGA 0/1 or PGA 0/1 responses are presented in Figure 6. The corresponding forest plot is detailed in Supplementary Figure 3.

Figure 6: Relative risk with 95% CIs of all interventions from network meta-analysis for sPGA 0/1 or IGA 0/1 or PGA 0/1 responses. Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if , it favors the column defining treatment. In contrast, if , it favors the row defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.

(4) AEs. In terms of having a risk of AEs, the rate was higher in secukinumab 300 mg, secukinumab 150 mg, ustekinumab 45 mg, brodalumab 210 mg and brodalumab 140 mg, ixekizumab 80 mg every 4 weeks, and ixekizumab 80 mg every 2 weeks compared to placebo. The effect size was the strongest for ixekizumab 80 mg every 4 weeks (, 95% CI 1.15, 1.37) and ixekizumab 80 mg every 2 weeks (, 95% CI 1.14, 1.36). In the mixed comparisons, secukinumab 150 mg was more likely to result in AEs than ustekinumab 90 mg (, 95% CI 1.05, 1.35), tildrakizumab 200 mg (, 95% CI 1.11, 1.49), and tildrakizumab 100 mg (, 95% CI 1.10, 1.48). There was no significant difference between ixekizumab 80 mg every 2 weeks and ixekizumab 80 mg every 4 weeks (, 95% CI 0.94, 1.08). Network meta-analysis results for AEs are presented in Figure 7. The corresponding forest plot is detailed in Supplementary Figure 4.

Figure 7: Relative risk with 95% CIs of all interventions from network meta-analysis for adverse events(AEs). Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if , it favors the row defining treatment. In contrast, if , it favors the column defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.

(5) sAEs. In terms of having a risk of sAEs, no significant difference was observed between these biologics and placebo. Besides, in the mixed comparisons, the rate was higher in ixekizumab 80 mg every 4 weeks compared to risankizumab 150 mg (, 95% CI 1.01, 8.77). Network meta-analysis results for sAEs are presented in Figure 8. The corresponding forest plot is detailed in Supplementary Figure 5.

Figure 8: Relative risk with 95% CIs of all interventions from network meta-analysis for serious adverse events (sAEs). Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if , it favors the row defining treatment. In contrast, if , it favors the column defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.

(6) Discontinuations due to AEs. In terms of having a risk of discontinuations due to AEs, ustekinumab 45 mg and risankizumab 150 mg present a relatively lower risk than placebo; RR were 0.47 (95% CI 0.24, 0.93) and 0.22 (95% CI 0.06, 0.79), respectively. In the mixed comparisons, ixekizumab 80 mg every 4 weeks was more likely to result in discontinuations due to AEs than ustekinumab 45 mg (, 95% CI 1.45, 11.44), risankizumab 150 mg (, 95% CI 1.95, 39.08), and guselkumab 50 mg (, 95% CI 1.06, 46.91). Network meta-analysis results for discontinuations are presented in Figure 9. The corresponding forest plot is detailed in Supplementary Figure 6.

Figure 9: Relative risk with 95% CIs of all interventions from network meta-analysis for Discontinuations due to AEs. Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if , it favors the row defining treatment. In contrast, if , it favors the column defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.

3.4. Ranking of Treatments by Efficacy

The summarized efficacy and safety ranking of the 13 interventions according to their surface under the cumulative ranking curves (SUCRA) are shown in Table 3; SUCRA for each treatment included in the network are presented in Figure 10. The ranking for short-term achievements of PASI 75 from high to low was as follows: ixekizumab 80 mg every 2 weeks (SUCRA: 93.0%), secukinumab 300 mg (SUCRA: 89.9%), ixekizumab 80 mg every 4 weeks (SUCRA: 81.5%), secukinumab 150 mg (SUCRA: 73.5%), brodalumab 210 mg (SUCRA: 62.5%), risankizumab 150 mg (SUCRA: 62.3%), ustekinumab 90 mg (SUCRA: 44.5%), tildrakizumab 200 mg (SUCRA: 42.2%), guselkumab 50 mg (SUCRA: 38.7%), tildrakizumab 100 mg (SUCRA: 33.2%), guselkumab 100 mg (SUCRA: 28.5%), ustekinumab 45 mg (SUCRA: 27.4%), and brodalumab 140 mg (SUCRA: 22.8%). The ranking for short-term achievements of PASI 100 from high to low was as follows: brodalumab 210 mg (SUCRA: 85.0%), ixekizumab 80 mg every 2 weeks (SUCRA: 83.3%), ixekizumab 80 mg every 4 weeks (SUCRA: 76.8%), risankizumab 150 mg (SUCRA: 71.3%), brodalumab 140 mg (SUCRA: 63.4%), secukinumab 300 mg (SUCRA: 62.4%), guselkumab 100 mg (SUCRA: 61.4%), guselkumab 50 mg (SUCRA: 55.9%), ustekinumab 90 mg (SUCRA: 34.5%), ustekinumab 45 mg (SUCRA: 33.1%), secukinumab 150 mg (SUCRA: 31.0%), tildrakizumab 100 mg (SUCRA: 21.9%), and tildrakizumab 200 mg (SUCRA: 20.0%). The ranking for short-term achievements of sPGA 0/1 or IGA 0/1 or PGA 0/1 from high to low was as follows: secukinumab 300 mg (SUCRA: 98.1%), ixekizumab 80 mg every 2 weeks (SUCRA: 86.5%), secukinumab 150 mg (SUCRA: 85.7%), ixekizumab 80 mg every 4 weeks (SUCRA: 75.7%), risankizumab 150 mg (SUCRA: 66.7%), brodalumab 210 mg (SUCRA: 65.4%), ustekinumab 90 mg (SUCRA: 42.8%), tildrakizumab 200 mg (SUCRA: 34.7%), guselkumab 50 mg (SUCRA: 33.4%), brodalumab 140 mg (SUCRA: 32.0%), guselkumab 100 mg (SUCRA: 31.4%), ustekinumab 45 mg (SUCRA: 25.4%), and tildrakizumab 100 mg (SUCRA: 22.3%).

Table 3: Ranking for all the outcomes of the interventions included at 12 or 16 weeks in the network meta-analysis.

Interventions
PASI 75
PASI 100
sPGA 0/1 or IGA 0/1 or PGA 0/1
AEs
sAEs
Discontinuations due to AEs

SUCRA (%)
PrBest
MeanRank
SUCRA (%)
PrBest
MeanRank
SUCRA (%)
PrBest
MeanRank
SUCRA (%)
PrHighest risk
MeanRank
SUCRA (%)
PrHighest risk
MeanRank
SUCRA (%)
PrHighest risk
MeanRank

Brodalumab 140 mg
22.8
0.0
11.0
63.4
0.5
5.8
32.0
0.0
9.8
38.1
0.0
9.0
38.4
0.1
9.0
54.2
0.6
7.0

Brodalumab 210 mg
62.5
0.3
5.9
85.0
28.4
2.9
65.4
0.1
5.5
23.7
0.0
10.9
63.9
3.8
5.7
63.0
0.9
5.8

Guselkumab 100 mg
28.5
0.0
10.3
61.4
6.0
6.0
31.4
0.0
9.9
63.4
1.3
5.8
49.4
3.3
7.6
32.1
0.2
9.8

Guselkumab 50 mg
38.7
0.4
9.0
55.9
4.3
6.7
33.4
0.0
9.7
76.2
30.1
4.1
25.9
3.5
10.6
84.6
36.7
3.0

Ixekizumab 80 mg Q2W
93.0
53.4
1.9
83.3
32.7
3.2
86.5
13.3
2.8
7.5
0.0
13.0
50.8
3.1
7.4
14.8
0.0
12.1

Ixekizumab 80 mg Q4W
81.5
0.5
3.4
76.8
12.9
4.0
75.7
0.0
4.2
4.5
0.0
13.4
27.5
0.5
10.4
10.7
0.0
12.6

Placebo
0.0
0.0
14.0
0.0
0.0
14.0
0.0
0.0
14.0
67.3
0.0
5.3
59.4
0.1
6.3
39.7
0.0
8.8

Risankizumab 150 mg
62.3
0.4
5.9
71.3
6.4
4.7
66.7
0.4
5.3
67.6
5.3
5.2
92.8
61.5
1.9
92.6
53.2
2.0

Secukinumab 150 mg
73.5
0.0
4.4
31
0.1
10.0
85.7
0.0
2.9
22.7
0.0
11.0
30.7
0.4
10.0
43.5
0.2
8.4

Secukinumab 300 mg
89.9
43.1
2.3
62.4
8.3
5.9
98.1
86.0
1.3
33.9
0.0
9.6
35.6
0.9
9.4
42.2
0.1
8.5

Tildrakizumab 100 mg
33.2
0.2
9.7
21.9
0.4
11.2
22.3
0.0
11.1
88.8
27.9
2.5
70.8
18.9
4.8
58.6
4.5
6.4

Tildrakizumab 200 mg
42.2
1.7
8.5
20.0
0.0
11.4
34.7
0.2
9.5
90.2
31.3
2.3
41.1
1.2
8.7
35.4
0.4
9.4

Ustekinumab 45 mg
27.4
0.0
10.4
33.1
0.0
9.7
25.4
0.0
10.7
41.0
0.0
8.7
61.1
0.6
6.1
79.0
3.0
3.7

Ustekinumab 90 mg
44.5
0.0
8.2
34.5
0.0
9.5
42.8
0.0
8.4
75.2
4.1
4.2
52.5
2.1
7.2
49.7
0.2
7.5

SUCRA: surface under the cumulative ranking; PrBest: probability of best treatment; PrHighest risk: probability of the highest risk of AEs; PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events; Q2W: every 2 weeks; Q4W: every 4 weeks.

(a) PASI 75

(b) PASI 100

(c) sPGA 0/1 or IGA 0/1 or PGA 0/1

(d) AEs

(e) sAEs

(f) Discontinuations due to AEs

Figure 10: Surface under the cumulative ranking curves (SUCRA) for all interventions of all outcomes in the network meta-analysis. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events. Alphabetic reference: A, brodalumab 140 mg; B, brodalumab 210 mg, C, guselkumab 100 mg; D, guselkumab 50 mg; E, ixekizumab 80 mg Q2W; F, ixekizumab 80 mg Q4W; G, placebo; H, risankizumab 150 mg; I, secukinumab 150 mg; J, secukinumab 300 mg; K, tildrakizumab 100 mg; L, tildrakizumab 200 mg; M, ustekinumab 45 mg; and N, ustekinumab 90 mg.

3.5. Ranking of Treatments by Safety

According to the SUCRA, the ranking for the short-term risk of adverse events from high to low was as follows: ixekizumab 80 mg every 4 weeks (SUCRA: 4.5%), ixekizumab 80 mg every 2 weeks (SUCRA: 7.5%), secukinumab 150 mg (SUCRA: 22.7%), brodalumab 210 mg (SUCRA: 23.7%), secukinumab 300 mg (SUCRA: 33.9%), brodalumab 140 mg (SUCRA: 38.1%), ustekinumab 45 mg (SUCRA: 41.0%), guselkumab 100 mg (SUCRA: 63.4%), risankizumab 150 mg (SUCRA: 67.6%), ustekinumab 90 mg (SUCRA: 75.2%), guselkumab 50 mg (SUCRA: 76.2%), tildrakizumab 100 mg (SUCRA: 88.8%), and tildrakizumab 200 mg (SUCRA: 90.2%). The ranking for the short-term risk of serious adverse events from high to low was as follows: guselkumab 50 mg (SUCRA: 25.9%), ixekizumab 80 mg every 4 weeks (SUCRA: 27.5%), secukinumab 150 mg (SUCRA: 30.7%), secukinumab 300 mg (SUCRA: 35.6%), brodalumab 140 mg (SUCRA: 38.4%), tildrakizumab 200 mg (SUCRA: 41.1%), guselkumab 100 mg (SUCRA: 49.4%), ixekizumab 80 mg every 2 weeks (SUCRA: 50.8%), ustekinumab 90 mg (SUCRA: 52.5%), ustekinumab 45 mg (SUCRA: 61.1%), brodalumab 210 mg (SUCRA: 63.9%), tildrakizumab 100 mg (SUCRA: 70.8%), and risankizumab 150 mg (SUCRA: 92.8%). The ranking for the short-term risk of discontinuations due to adverse events from high to low was as follows: ixekizumab 80 mg every 4 weeks (SUCRA: 10.7%), ixekizumab 80 mg every 2 weeks (SUCRA: 14.8%), guselkumab 100 mg (SUCRA: 32.1%), tildrakizumab 200 mg (SUCRA: 35.4%), secukinumab 300 mg (SUCRA: 42.2%), secukinumab 150 mg(SUCRA: 43.5%), ustekinumab 90 mg (SUCRA: 49.7%), brodalumab 140 mg (SUCRA: 54.2%), tildrakizumab 100 mg (SUCRA: 58.6%), brodalumab 210 mg (SUCRA: 63.0%), ustekinumab 45 mg (SUCRA: 79.0%), guselkumab 50 mg (SUCRA: 84.6%), and risankizumab 150 mg (SUCRA: 92.6%).

3.6. Inconsistency

Inconsistency refers to the difference between direct and indirect evidences, which will affect the authenticity of network meta-analysis. We used the relative odds ratio (ROR) with 95% CIs to calculate the absolute difference between direct and indirect evidences. If the ROR is close to 1, or the 95% CIs include 0, the effect estimations for direct and indirect evidences are consistent. The results of PASI 100, sPGA 0/1 or IGA 0/1 or PGA 0/1, AEs, sAEs, and discontinuations due to AEs showed no significant inconsistencies in all closed loops which revealed the consistency model’s conclusions were robust. For PASI 75, there was statistical loop inconsistency in the loop containing placebo, ustekinumab 45 mg, and ustekinumab 90 mg in the combined results of direct and indirect evidences (, 95% CI 1.36, 3.28). Inconsistency plots in closed loops for all the outcomes are shown in Figure 11.

(a) PASI 75

(b) PASI 100

(c) sPGA 0/1 or IGA 0/1 or PGA 0/1

(d) AEs

(e) sAEs

(f) Discontinuations due to AEs

Figure 11: Inconsistency in closed loops for all the outcomes. The graph shows the estimates of differences between direct and indirect comparisons as represented by the relative odds ratio (ROR) with 95% CIs. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events. Alphabetic reference: A, brodalumab 140 mg; B, brodalumab 210 mg; C, guselkumab 100 mg; D, guselkumab 50 mg; E, ixekizumab 80 mg Q2W; F, ixekizumab 80 mg Q4W; G, placebo; H, risankizumab 150 mg; I, secukinumab 150 mg; J, secukinumab 300 mg; K, tildrakizumab 100 mg; L, tildrakizumab 200 mg; M, ustekinumab 45 mg; and N, ustekinumab 90 mg.

3.7. Sensitivity Analysis

Considered PASI 100 and sPGA 0/1 or IGA 0/1 or PGA 0/1 responses are more relevant to the psoriasis patient, we performed sensitivity analyses with these outcomes by excluding the trials at a high risk of bias to evaluate the robustness of our findings. Results were consistent with the main analysis for the efficacy outcomes. And the forest plots are detailed in Supplementary Figure 7-8.

3.7.1. Publication Bias

Comparison-adjusted funnel plots of all the outcomes in network meta-analysis are shown in Figure 12. We found no evidence of publication bias in the result of “AEs” and “discontinuations due to AEs.” However, the results of other outcomes were not absolutely symmetrical which suggested publication bias may exist.

(a) PASI 75

(b) PASI 100

(c) sPGA 0/1 or IGA 0/1 or PGA 0/1

(d) AEs

(e) sAEs

(f) Discontinuations due to AEs

Figure 12: Comparison-adjusted funnel plots of all the outcomes in network meta-analysis. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events. Alphabetic reference: A, brodalumab 140 mg; B, brodalumab 210 mg; C, guselkumab 100 mg; D, guselkumab 50 mg; E, ixekizumab 80 mg Q2W; F, ixekizumab 80 mg Q4W; G, placebo; H, risankizumab 150 mg; I, secukinumab 150 mg; J, secukinumab 300 mg; K, tildrakizumab 100 mg; L, tildrakizumab 200 mg; M, ustekinumab 45 mg; and N, ustekinumab 90 mg.

4. Discussion

In recent years, biological agents have been widely used in dermatology, especially in patients with chronic psoriasis. Many clinical trials have shown that biological agents can quickly control the illness and improve life quality. Meanwhile, the safety of biological agents has also attracted the attention of dermatologists. Therefore, we summarized and evaluated the short-term therapeutic efficacy and safety of IL-17, IL-12/23, and IL-23 biological agents for the treatment of moderate to severe plaque psoriasis. We extracted direct and indirect evidences from 28 trials with 19840 patients into this meta-analysis. Among these studies, except for 7 phase II trials [17, 18, 20, 24, 29, 30, 32], the others were all phase III trials. All of them were placebo-controlled, and a parallel assignment study contained at least two different doses with the exception of 2 trials that included only one dose with no active controller [19, 23]. In addition, the primary endpoints were all assessed at 12 or 16 weeks.

In order to make the efficacy and safety data of these medications comparable, we performed a NMA to compare the indirect evidences in this quantitative meta-analysis. We found that all biologics involved were more efficacious than placebo in achieving PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 responses. IL-17 inhibitors achieved outstanding performance in the treatment effect at 12 weeks compared with IL-12/23 and IL-23 inhibitors. For PASI 75, ixekizumab 80 mg every 2 weeks ranked first, followed by secukinumab 300 mg, ixekizumab 80 mg every 4 weeks, secukinumab 150 mg and brodalumab 210 mg. For PASI 100, brodalumab 210 mg ranked first, followed by ixekizumab 80 mg every 2 weeks and ixekizumab 80 mg every 4 weeks. Studies showed that about 42% of patients treated with brodalumab 210 mg reached PASI 100 at 12 weeks, while only 0.4% of patients treated with placebo reached PASI 100 at 12 weeks [28]. For sPGA 0/1 or IGA 0/1 or PGA 0/1 responses, secukinumab 300 mg ranked first, followed by ixekizumab 80 mg every 2 weeks, secukinumab 150 mg, ixekizumab 80 mg every 4 weeks and risankizumab 150 mg. In addition, three trials of ixekizumab observed the improvement of the Dermatological Life Quality Index (DLQI) in patients with moderate to severe plaque psoriasis. Data showed that DLQI improved rapidly in the second week after the treatment with ixekizumab, and more than 60% of patients received DLQI (0/1) at 12 weeks without psoriasis symptoms [35, 36]. It was noteworthy that in the use of brodalumab, secukinumab, and ixekizumab, high-dose drugs or high-frequency drugs were more effective than low-dose drugs or low-frequency drugs. Risankizumab is a new type of IL-23 inhibitor, whose short-term efficacy was better than other IL-23 or IL-12/23 inhibitors. The results for short-term safety assessment showed that the risk of adverse events in brodalumab 210 mg, brodalumab 140 mg, secukinumab 300 mg, secukinumab 150 mg, ixekizumab 80 mg every 4 weeks, ixekizumab 80 mg every 2 weeks, and ustekinumab 45 mg was higher than that in the placebo group at 12 or 16 weeks. It showed that IL-17 inhibitors were less tolerant than other biological agents. It was also worth noting that the tolerance of ixekizumab 80 mg every 4 weeks was often worse than that of ixekizumab 80 mg every 2 weeks and was associated with greater likelihood of causing sAEs and discontinuations. There was no significant difference in the short-term adverse event risk between other biological agents and placebo. According to the clinical trials, the most relevant adverse events were nasopharyngitis, upper respiratory tract inflammation, and injection site reaction. Guselkumab is a kind of biological therapy that selectively blocked IL-23 [37]. In the 100 mg treatment group, the short-term risk of adverse events was lower than that of other biological agents; however, the risk of discontinuations was high, which may limit its clinical use. In the 50 mg treatment group, the short-term risk of adverse events and discontinuations was low, but the risk of serious adverse events ranked first, so a long-term follow-up of guselkumab is necessary to examine its treatment tolerability. The present meta-analysis included a kind of IL-12/23 inhibitor named ustekinumab which blocked not only the IL-12 but also the IL-23 [38]. Though the risk of adverse events was higher in ustekinumab 45 mg than that in placebo, the risk of discontinuations in the ustekinumab 45 mg and risankizumab 150 mg groups was lower than that in placebo. In ustekinumab 45 mg, only 6 out of 1013 patients abandoned treatment because of adverse events, while 23 out of 983 patients in the placebo group. In the risankizumab 150 mg, 3 out of 598 patients abandoned treatment because of adverse events, while 5 out of 200 patients in the placebo group [18–23, 34]. Not only that, risankizumab 150 mg had a lower risk of adverse events and serious adverse events compared with other IL-23 inhibitors, showing relatively high clinical efficacy and low treatment risk.

Our findings indicated efficacy and safety differences among the biologic agents used in moderate to severe plaque psoriasis which could provide valuable references to clinicians. The strengths in, firstly, our research included the latest biological agents for psoriasis treatment. Tildrakizumab had been licensed for treating psoriasis patients by the FDA in March 2018, and risankizumab had been approved by the FDA in Apirl 2019. Secondly, our study included a large number of patients and high quality of RCTs availabled at present. We compared different drugs at the dose level which not only increased the credibility of our research but also provided more information to the clinicians. Thirdly, previous studies took more attention on PASI 75 and PASI 90. However, PASI 100 is more relevant to the patients. In order to better reflect the efficacy of these drugs, we included PASI 100 in the evaluation of the primary outcomes.

Some potential limitations could affect the interpretation of our findings. Firstly, a placebo-controlled study was conducted during the induction period; however, the study design of the maintenance stage varied and usually the lack of a placebo-control group which increased the difficulty to extract and analyze all the data. So we evaluated the primary endpoints at the end of the induction period (12-16 weeks), whether the biologic agents can ultimately improve the quality of life of psoriasis patients is still unclear and requires more researches to continue. Secondly, some studies lack details of randomization sequence generation, allocation concealment, and blinding, which could reduce the reliability of our results. Therefore, to ensure the authenticity of the results, we made a sensitivity analysis with these outcomes by excluding the trials at a high risk of bias to evaluate the robustness of our findings. Results were consistent with the main analysis for the efficacy outcomes which could strengthen our analysis. Thirdly, few head to head trials available in our NMA, and most of the analyses were based on the indirect comparisons which may limit the consistency evaluation. Fourthly, there were more Americans and Canadians involved in the trials than Asians, so the results of this analysis may not be generalized to all the people in the world. Finally, the analysis has not considered the different medical histories of the patients, which may affect the findings and results.

5. Conclusions

IL-17, IL-12/23, and IL-23 inhibitors had high efficacy in the achievement of PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 in moderate to severe plaque psoriasis after 12 or 16 weeks of treatment. IL-17 inhibitors brodalumab, secukinumab, and ixekizumab showed superior efficacy in current clinical trials. However, the clinical safety of IL-17 inhibitors was weaker than that of IL-12/23 and IL-23 inhibitors. Ustekinumab was the only IL-12/23 inhibitor included in this study which performed mediocre in both efficacy and tolerance. The IL-23 inhibitor risankizumab is an excellent performer with high efficacy and low risk. The clinical tolerance of other biological agents needs to be further observed. These results may provide a new choice for a clinical treatment of plaque psoriasis. However, further clinical head to head trials are needed to confirm the long-term efficacy and safety of action of the interventions. And treatment decisions should also be based on the associated cost-effectiveness.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

FB and HM are responsible for the conception and design of the study. GL, FB, QL, XN, and RL are assigned to the acquisition of data and analysis. FB, GL, and HM wrote and revised the manuscript. All authors read and approved the final manuscript.

Supplementary Materials

Supplementary Table 1: search strategy. Supplementary Figure 1: interval plot between interventions versus placebo of achieving PASI 75 at 12 or 16 weeks in network meta-analysis. Supplementary Figure 2: interval plot between interventions versus placebo of achieving PASI 100 at 12 or 16 weeks in network meta-analysis. Supplementary Figure 3: interval plot between interventions versus placebo of achieving sPGA 0/1 or IGA 0/1 or PGA 0/1 at 12 or 16 weeks in network meta-analysis. Supplementary Figure 4: interval plot between interventions versus placebo of achieving one or more AEs at 12 or 16 weeks in network meta-analysis. Supplementary Figure 5: interval plot between interventions versus placebo of achieving one or more sAEs at 12 or 16 weeks in network meta-analysis. Supplementary Figure 6: interval plot between interventions versus placebo of discontinuations due to AEs at 12 or 16 weeks in network meta-analysis. Supplementary Figure 7: interval plot of sensitivity analyses by excluding the trials at the high risk of bias for achieving PASI 100 at 12 or 16 weeks. Supplementary Figure 8: interval plot of sensitivity analyses by excluding the trials at the high risk of bias for achieving sPGA 0/1 or IGA 0/1 or PGA 0/1 at 12 or 16 weeks. (Supplementary Materials)

References

R. S. Stern, “Psoriasis,” The Lancet, vol. 350, no. 9074, pp. 349–353, 1997.

I. M. Michalek, B. Loring, and S. M. John, “A systematic review of worldwide epidemiology of psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 31, no. 2, pp. 205–212, 2017.

R. Parisi, D. P. Symmons, C. E. Griffiths, D. M. Ashcroft, and on behalf of the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team, “Global epidemiology of psoriasis: a systematic review of incidence and prevalence,” Journal of Investigative Dermatology, vol. 133, no. 2, pp. 377–385, 2013.

J. E. Hawkes, T. C. Chan, and J. G. Krueger, “Psoriasis pathogenesis and the development of novel targeted immune therapies,” The Journal of Allergy and Clinical Immunology, vol. 140, no. 3, pp. 645–653, 2017.

L. van der Fits, S. Mourits, J. S. A. Voerman et al., “Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis,” Journal of Immunology, vol. 182, no. 9, pp. 5836–5845, 2009.

A. Di Cesare, P. Di Meglio, and F. O. Nestle, “The IL-23/Th17 axis in the immunopathogenesis of psoriasis,” The Journal of Investigative Dermatology, vol. 129, no. 6, pp. 1339–1350, 2009.

D. C. Torti and S. R. Feldman, “Interleukin-12, interleukin-23, and psoriasis: current prospects,” Journal of the American Academy of Dermatology, vol. 57, no. 6, pp. 1059–1068, 2007.

J. Bilal, A. Berlinberg, S. Bhattacharjee, J. Trost, I. B. Riaz, and D. J. B. Kurtzman, “A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis,” The Journal of Dermatological Treatment, vol. 29, no. 6, pp. 569–578, 2018.

L. Cui, R. Chen, S. Subedi et al., “Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials,” International Immunopharmacology, vol. 62, pp. 46–58, 2018.

Z. K. Jabbar-Lopez, Z. Z. N. Yiu, V. Ward et al., “Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis,” The Journal of Investigative Dermatology, vol. 137, no. 8, pp. 1646–1654, 2017.

B. Hutton, G. Salanti, D. M. Caldwell et al., “The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations,” Annals of Internal Medicine, vol. 162, no. 11, pp. 777–784, 2015.

I. R. White, J. K. Barrett, D. Jackson, and J. P. T. Higgins, “Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression,” Research Synthesis Methods, vol. 3, no. 2, pp. 111–125, 2012.

G. Salanti, A. E. Ades, and J. P. A. Ioannidis, “Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial,” Journal of Clinical Epidemiology, vol. 64, no. 2, pp. 163–171, 2011.

C. Paul, J. P. Lacour, L. Tedremets et al., “Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE),” Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 6, pp. 1082–1090, 2015.

A. Blauvelt, J. C. Prinz, A. B. Gottlieb et al., “Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE),” The British Journal of Dermatology, vol. 172, no. 2, pp. 484–493, 2015.

R. G. Langley, B. E. Elewski, M. Lebwohl et al., “Secukinumab in plaque psoriasis--results of two phase 3 trials,” The New England Journal of Medicine, vol. 371, no. 4, pp. 326–338, 2014.

P. Rich, B. Sigurgeirsson, D. P. Thaci et al., “Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study,” The British Journal of Dermatology, vol. 168, pp. 402–411, 2013.

G. G. Krueger, R. G. Langley, C. Leonardi et al., “A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis,” The New England Journal of Medicine, vol. 356, no. 6, pp. 580–592, 2007.

T. F. Tsai, J. C. Ho, M. Song et al., “Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL),” Journal of Dermatological Science, vol. 63, no. 3, pp. 154–163, 2011.

A. Igarashi, T. Kato, M. Kato, M. Song, H. Nakagawa, and The Japanese Ustekinumab Study Group, “Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial,” Journal of Dermatology, vol. 39, no. 3, pp. 242–252, 2012.

K. A. Papp, R. G. Langley, M. Lebwohl et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2),” The Lancet, vol. 371, no. 9625, pp. 1675–1684, 2008.

C. L. Leonardi, A. B. Kimball, K. A. Papp et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1),” The Lancet, vol. 371, no. 9625, pp. 1665–1674, 2008.

X. Zhu, M. Zheng, M. Song et al., “Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial(LOTUS),” Journal of Drugs in Dermatology, vol. 12, no. 2, pp. 166–174, 2013.

K. B. Gordon, K. C. Duffin, R. Bissonnette et al., “A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis,” The New England Journal of Medicine, vol. 373, no. 2, pp. 136–144, 2015.

K. Reich, A. W. Armstrong, P. Foley et al., “Efficacy and safety of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: results from the phase 3, double-blind, placebo-and active comparator-controlled VOYAGE 2 trial,” Journal of the American Academy of Dermatology, vol. 76, no. 6, article AB111, 2017.

A. Blauvelt, K. A. Papp, C. E. Griffiths et al., “Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial,” Journal of the American Academy of Dermatology, vol. 76, no. 3, pp. 405–417, 2017.

M. Ohtsuki, H. Kubo, H. Morishima, R. Goto, R. Zheng, and H. Nakagawa, “Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study,” The Journal of Dermatology, vol. 45, no. 9, pp. 1053–1062, 2018.

K. A. Papp, K. Reich, C. Paul et al., “A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis,” The British Journal of Dermatology, vol. 175, no. 2, pp. 273–286, 2016.

H. Nakagawa, H. Niiro, K. Ootaki, and Japanese brodalumab study group, “Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study,” Journal of Dermatological Science, vol. 81, no. 1, pp. 44–52, 2016.

K. A. Papp, C. Leonardi, A. Menter et al., “Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis,” The New England Journal of Medicine, vol. 366, no. 13, pp. 1181–1189, 2012.

M. Lebwohl, B. Strober, A. Menter et al., “Phase 3 studies comparing brodalumab with ustekinumab in psoriasis,” The New England Journal of Medicine, vol. 373, no. 14, pp. 1318–1328, 2015.

K. Papp, D. Thaçi, K. Reich et al., “Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial,” The British Journal of Dermatology, vol. 173, no. 4, pp. 930–939, 2015.

K. Reich, K. A. Papp, A. Blauvelt et al., “Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials,” The Lancet, vol. 390, no. 10091, pp. 276–288, 2017.

K. B. Gordon, B. Strober, M. Lebwohl et al., “Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials,” Lancet, vol. 392, no. 10148, pp. 650–661, 2018.

C. E. M. Griffiths, K. Reich, M. Lebwohl et al., “Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials,” The Lancet, vol. 386, no. 9993, pp. 541–551, 2015.

K. B. Gordon, A. Blauvelt, K. A. Papp et al., “Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis,” The New England Journal of Medicine, vol. 375, no. 4, pp. 345–356, 2016.

S. T. Howell, L. A. Cardwell, and S. R. Feldman, “Treating moderate-to-severe plaque psoriasis with guselkumab: a review of phase II and phase III trials,” Annals of Pharmacotherapy, vol. 52, no. 4, pp. 380–387, 2018.

S. Famenini and J. J. Wu, “The efficacy of ustekinumab in psoriasis,” Journal of Drugs in Dermatology, vol. 12, no. 3, pp. 317–320, 2013.